Combined psychotherapy plus benzodiazepines for panic disorder (Q24240927)

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Alprazolam and exposure for panic disorder with agoraphobia. Attribution of improvement to medication predicts subsequent relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Relationship of panic, anticipatory anxiety, agoraphobia and global improvement in panic disorder with agoraphobia treated with alprazolam and exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Long-term effects of alprazolam on memory: a 3.5 year follow-up of agoraphobia/panic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Drug treatment of panic disorder. Further comment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Changes in "withdrawal symptoms" following discontinuation of low-dose diazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Effects of concurrent diazepam treatment on the outcome of exposure therapy in agoraphobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Exposure and communications training in the treatment of agoraphobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Alprazolam in the treatment of generalized anxiety and panic disorders: A double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Arousal Levels and Attribution Effects in Diazepam-Assisted Flooding

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Effectiveness of cognitive--behavioral treatment for panic disorder versus treatment as usual in a managed care setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

What treatments do patients with panic disorder and agoraphobia get?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Cognitive Effects of Long-Term Benzodiazepine Use

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

12-month prevalence of panic disorder with or without agoraphobia in the Swedish general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Bias in treatment assignment in controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

The Mobility Inventory for Agoraphobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

How study design affects outcomes in comparisons of therapy. I: Medical

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

The assessment of anxiety states by rating

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Self-exposure therapy for panic disorder with agoraphobia: randomised controlled study of external v. interoceptive self-exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

A comparison of delivery methods of cognitive-behavioral therapy for panic disorder: an international multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Lifetime panic-depression comorbidity in the National Comorbidity Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Brief standard self-rating for phobic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

New Evidence on Benzodiazepine Use and Falls: The Time Factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Diazepam and Propranolol in Panic Disorder and Agoraphobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

A consumer's guide to subgroup analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Lactate-induced anxiety after imipramine and diazepam treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Affective comorbidity in panic disorder: is there a bipolar connection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Multicenter collaborative panic disorder severity scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Longitudinal outcome with pharmacotherapy in a naturalistic study of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Benzodiazepines and exposure-based cognitive behavior therapies for panic disorder: conclusions from combined treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Treatment of panic disorder with agoraphobia in an anxiety disorders clinic: factors influencing psychiatrists' treatment choices

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Group cognitive-behavioral treatment of panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Behaviour therapy and benzodiazepines: allies or antagonists?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Suicidal ideation and suicide attempts in panic disorder and attacks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

The cross-national epidemiology of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Cognitive behavioural therapy and pharmacotherapy: complementary or contradictory approaches to the treatment of anxiety?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Naturalistic manner of benzodiazepine use and cognitive behavioral therapy outcome in panic disorder with agoraphobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Imputing response rates from means and standard deviations in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

Double-blindness procedures, rater blindness, and ratings of outcome. Observations from a controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

7 January 2021

Cognitive and performance-based treatments for panic attacks in people with varying degrees of agoraphobic disability

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

7 January 2021

Pre-treatment predictors of treatment outcome in panic disorder and agoraphobia treated with alprazolam and exposure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

7 January 2021

Risk of traffic accident injury after a prescription for a benzodiazepine☆

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

7 January 2021

Does concurrent drug intake affect the long-term outcome of group cognitive behaviour therapy in panic disorder with or without agoraphobia?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

7 January 2021

Exposure in vivo of agoraphobics: contributions of diazepam, group exposure, and anxiety evocation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

7 January 2021

Long-term outcome of panic disorder with agoraphobia treated by exposure.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

7 January 2021

Assessment of fear of fear in agoraphobics: the body sensations questionnaire and the agoraphobic cognitions questionnaire.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

7 January 2021

Long-term outcome in cognitive-behavioral treatment of panic disorder: Clinical predictors and alternative strategies for assessment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

7 January 2021

Impact of cognitive-behavioral treatment on quality of life in panic disorder patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

7 January 2021

Brief cognitive therapy for panic disorder: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

7 January 2021

A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

7 January 2021

Panic disorder: long-term pharmacotherapy and discontinuation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

7 January 2021

Duration of imipramine therapy and relapse in panic disorder with agoraphobia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

7 January 2021

The measurement of disability.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

7 January 2021

The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

7 January 2021

A crossover study of focused cognitive therapy for panic disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

7 January 2021

Discontinuation of benzodiazepine treatment: efficacy of cognitive- behavioral therapy for patients with panic disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

7 January 2021

Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

7 January 2021

Alprazolam withdrawal symptoms in agoraphobia with panic disorder: observations from a controlled Anglo-Canadian study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

7 January 2021

Comment on the London/Toronto Study of Alprazolam and Exposure in Panic Disorder with Agoraphobia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

7 January 2021

Panic disorder with agoraphobia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005335.PUB2

7 January 2021